Screener / SEC EDGAR /CIK 0001757073 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Dental Equipment & Supplies

Envista Holdings Corp NVST

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. 10-K, Item 1

Headquarters
Brea, CA
CEO
Paul A. Keel
Next results
around Feb 4, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.7B through the costs to a net profit of $47.0M · income statement of the 10-K

8% operating margin
Revenue to Gross profit: $1.5BRevenue to Cost of revenue: $1.2BGross profit to Operating profit: $216.1MGross profit to Operating expenses: $1.3BOperating profit to Net profit: $47.0MOperating profit to Tax & other: $169.1MOperating expenses to R&D: $114.0MOperating expenses to SG&A: $1.2B Revenue: $2.7B REVENUE $2.7B +8% Y/Y Gross profit: $1.5B · 55% margin GROSS PROFIT $1.5B 55% margin · +8% Y/Y Cost of revenue: $1.2B · 45% of revenue COST OF REVENUE $1.2B 45% of revenue Operating profit: $216.1M · 8% margin OPERATING PROFIT $216.1M 8% margin Operating expenses: $1.3B · 47% of revenue OPERATING EXPENSES $1.3B 47% of revenue Net profit: $47.0M · 2% margin NET PROFIT $47.0M 2% margin Tax & other: $169.1M · 6% of revenue TAX & OTHER $169.1M 6% of revenue R&D: $114.0M · 4% of revenue R&D $114.0M 4% of revenue SG&A: $1.2B · 43% of revenue SG&A $1.2B 43% of revenue
Gross profit $1.5B 55% margin · +8% Y/Y
Operating profit $216.1M 8% margin
Net profit $47.0M 2% margin
The full income statement, year by year

NVST among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 8.3%, above 42% of 154 peers (their median 10.5%) REVENUE GROWTH 8.3% · above 42% Gross margin: 55.9%, above 37% of 107 peers (their median 63.8%) GROSS MARGIN 55.9% · above 37% Operating margin: 25.4%, above 88% of 138 peers (their median 9.8%) OPERATING MARGIN 25.4% · above 88% Net margin: 22.0%, above 87% of 153 peers (their median 6.7%) NET MARGIN 22.0% · above 87% FCF margin: 8.4%, above 43% of 144 peers (their median 10.1%) FCF MARGIN 8.4% · above 43% Return on capital: 1.3%, above 2% of 89 peers (their median 9.2%) RETURN ON CAPITAL 1.3% · above 2%
NVST Peer median Below the median

What changed

1 new risk paragraph and 2 accounting facts worth reading about. 10-K filed Feb 12, 2026 against Feb 13, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +18.3% ($363.0M to $429.6M) vs revenue +8.3% ($2.5B to $2.7B), +10.0 pts apart
  • Inventory growing faster than revenue
    Inventory +19.5% ($241.0M to $288.1M) vs revenue +8.3% ($2.5B to $2.7B), +11.2 pts apart
  • Cash from operations $275.7M vs net income $47.0M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Goodwill Impairment; Indefinite-lived Intangible Asset Impairment
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

1 paragraph in Risk Factors that was not in the 10-K filed Feb 13, 2025. Quoted as filed.

  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    We are also subject to various laws regulating fraud and abuse, pricing and sales and marketing practices in the health care industry and the privacy and security of health information as well as manufacturing and quality standards, including the federal regulations described in “Item 1. Business —Regulatory Matters.” Ensuring that our…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.6B$2.6B$2.5B$2.7B
Net income$243.1M−$100.2M−$1.1B$47.0M
Operating cash flow$182.7M$275.7M$336.5M$275.7M
Free cash flow$107.0M$217.5M$302.7M$230.4M

Revenue, FY2017 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.7B ▲ 8.3% in FY2025

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Envista Holdings Corp, Brea, CA · from the 10-K filed Feb 12, 2026

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile.

Headquarters
Brea, CA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NVST/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.